CHI Memorial

Tocilizumab (Actemra) Use Criteria

Approved 2/10/2021; updated 3/29/2021; updated 5/31/2021; **updated 8/18/2021**

- COVID-19+
- Within 72 hours of supplemental oxygen requirement
- Patient rapidly decompensating within the past 24 hours
    - Rapidly increasing O2 requirements
    - Progressive pulmonary infiltrates over the past 24 hrs on chest x-ray
- Tocilizumab must be initiated within 24 hours of initiation of high flow nasal cannula, non-invasive ventilation
- C- reactive protein level must be ≥ 75 mcg/ml
- Patient must be receiving corticosteroids unless contraindicated
- Exclusions:
    - Mechanical ventilation/ECMO
    - AST/ALT >5x ULN
    - Neutropenia (ANC <500 cells/µL)
    - Thrombocytopenia (platelet count <50,000cells/µL)
    - Serious non-COVID-19 infection (ex: bacterial, fungal, TB etc.)
    - Treatment with a biologic immunomodulating drug in past 30 days (including baricitinib)
    - High risk for gastrointestinal perforation

Dose = 8 mg/kg IV dose (max 800 mg); single dose. Do not repeat dose.